<DOC>
	<DOC>NCT00545480</DOC>
	<brief_summary>This 2 arm study will assess the impact of bone marker feedback, using blood sampling and communication of results at week 5, on persistence to monthly Bonviva (150mg po) in women with post-menopausal osteoporosis. The study will also assess safety, quality of life and patient satisfaction. All patients will receive Bonviva 150mg po monthly, and will be randomized into the bio-feedback or no bio-feedback study arms. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.</brief_summary>
	<brief_title>SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>ambulatory, postmenopausal women who would benefit from bisphosphonate treatment; &gt;55 years of age; naive to bisphosphonate therapy, or lapsed bisphosphonate users &gt;=6 months. inability to stand or sit in an upright position for at least 60 minutes; hypersensitivity to bisphosphonates; treatment with other drugs affecting bone metabolism; history of major upper gastrointestinal disease.</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>